Estrogen receptor α mediated induction of the transforming growth factor α gene by estradiol and 4-hydroxytamoxifen in MDA-MB-231 breast cancer cells

Journal of Steroid Biochemistry and Molecular Biology

Volumn 78, Issue 1, 2001, Pages 41-50

  Macgregor Schafer, Jennifer ^a   Liu, Hong ^a   Levenson, Anait S ^a   Horiguchi, Jun ^a   Chen, Zehan ^a   Jordan, V Craig ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Antiestrogen; Breast cancer; ER; TGF

Indexed keywords

4 HYDROXYTAMOXIFEN; ANTIESTROGEN; CYCLOHEXIMIDE; DACTINOMYCIN; DNA; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FULVESTRANT; MESSENGER RNA; TRANSFORMING GROWTH FACTOR ALPHA;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG RESPONSE; GENE ACTIVATION; GENE INDUCTION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MUTANT; PROTEIN DNA INTERACTION; PROTEIN DOMAIN; PROTEIN EXPRESSION; TIME;

BLOTTING, NORTHERN; BLOTTING, WESTERN; CYCLOHEXIMIDE; DACTINOMYCIN; DNA, COMPLEMENTARY; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRADIOL; ESTROGEN ANTAGONISTS; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HUMANS; LUCIFERASES; PROTEIN SYNTHESIS INHIBITORS; RECEPTORS, ESTROGEN; RNA, MESSENGER; SIGNAL TRANSDUCTION; TAMOXIFEN; TIME FACTORS; TRANSCRIPTION, GENETIC; TRANSFECTION; TRANSFORMING GROWTH FACTOR ALPHA; TUMOR CELLS, CULTURED;

EID: 0034864373     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-0760(01)00072-3     Document Type: Article

References (59)

1. Blockade of the epidermal growth factor receptor inhibits transforming growth factor alpha-induced but not estrogen-induced growth of hormone-dependent human breast cancer
2. Prolonged treatment of breast cancer cells with antiestrogens increases the activating protein-1-mediated response: Involvement of the estrogen receptor
3. Differential response of estrogen receptor alpha and estrogen receptor beta to partial estrogen agonists/antagonists
4. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: Its regulation by estrogen and its possible functional significance
5. Role of the two activating domains of the oestrogen receptor in the cell-type and promoter-context dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen
6. Molecular basis of agonism and antagonism in the oestrogen receptor
7. Increasing the number of tandem estrogen response elements increases the estrogenic activity of a tamoxifen analogue
8. Tamoxifen for early breast cancer: An overview of the randomised trials
9. Estrogen induction of TGF-alpha is mediated by an estrogen response element composed of two imperfect palindromes
10. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study
11. Expression of wild-type estrogen receptor beta and variant isoforms in human breast cancer
12. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration
13. Human oestrogen receptor cDNA: Sequence, expression and homology to v-erb-A
14. Sequence and expression of human estrogen receptor complementary DNA
15. The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens
16. Nuclear receptor co-activators and co-repressors
17. Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
18. Paradoxical regulation of estrogen-dependent growth factor gene expression in estrogen receptor (ER)-negative human breast cancer cells stably expressing ER
19. Basic guides to the mechanism of estrogen action
20. Growth regulation of estrogen receptor-negative breast cancer cells transfected with complementary DNAs for estrogen receptor
21. Estrogen-stimulated prolactin synthesis in vitro: Classification of agonist, partial agonist and antagonist actions based on structure
22. Tamoxifen, raloxifene, and the prevention of breast cancer
23. Tripartite steroid hormone receptor pharmacology: Interaction with multiple effector sites as a basis for the cell- and promoter-specific action of these hormones
24. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor
25. Cloning of a novel receptor expressed in rat prostate and ovary
26. Comparison of ligand binding specificity and transcript tissue distribution of estrogen receptor α and β
27. A simple, rapid, and sensitive DNA assay procedure
28. Transforming growth factor alpha: Expression, regulation, and biological activities
29. Estrogenic activity is increased for an antiestrogen by a natural mutation of the estrogen receptor
30. The key to the antiestrogenic mechanism of raloxifene is amino acid 351 (aspartate) in the estrogen receptor
31. Selective oestrogen receptor modulation: Molecular pharmacology for the millennium
32. The oestrogen-like effect of 4-hydroxytamoxifen on induction of transforming growth factor alpha mRNA in MDA-MB-231 breast cancer cells stably expressing the oestrogen receptor
33. Mechanisms of growth control in normal and malignant breast epithelium
34. Transforming growth factor-alpha messenger RNA localization in the developing adult rat and human mammary gland by in situ hybridization
35. Analysis of estrogen receptor function in vitro reveals three distinct classes of antiestrogens
36. Different regions in activation function-1 of the human estrogen receptor required for antiestrogen- and estradiol-dependent transcription activation
37. Transcription activation by the human estrogen receptor subtype beta (ER beta) studied with ER beta and ER alpha receptor chimeras
38. An estrogen receptor-selective coregulator that potentiates the effectiveness of antiestrogens and represses the activity of estrogens
39. Regulation of transforming growth factor alpha and transforming growth factor beta messenger ribonucleic acid abundance in T-47D, human breast cancer cells
40. Peptide antagonists of the human estrogen receptor
41. Differential ligand activation of estrogen receptor ERα and ERβ at AP1 sites
42. Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and a full antagonist
43. Irreversible loss of the oestrogen receptor in T47D breast cancer cells following prolonged oestrogen deprivation
44. Models of estrogen receptor regulation by estrogens and antiestrogens in breast cancer cell lines
45. Transcriptional regulation of the human transforming growth factor-alpha gene
46. Regulation by estrogen through the 5′-flanking region of the transforming growth factor alpha gene
47. Transforming growth factors in human breast cancer
48. Modulation by estrogen and growth factors of transforming growth factor-alpha and epidermal growth factor receptor expression in normal and malignant human mammary epithelial cells
49. The interaction of raloxifene and the active metabolite of the antiestrogen (SC5705) with the human estrogen receptor (ER)
50. The structural basis of estrogen receptor/co-activator recognition and the antagonism of this interaction by tamoxifen
51. Expression and functional properties of transforming growth factor alpha and epidermal growth factor during mouse mammary gland ductal morphogenesis
52. Novel ligands that function as selective estrogens or antiestrogens for estrogen receptor-alpha or estrogen receptor-beta
53. Differences between estrogen- and antiestrogen-estrogen receptor complexes from human breast tumors identified with an antibody raised against the estrogen receptor
54. A receptor molecule for estrogens: Isolation from the rat uterus and preliminary characterization
55. Human estrogen receptor transactivational capacity is determined by both cellular and promoter context and mediated by two functionally distinct intramolecular regions
56. Expression of estrogen receptor beta messenger RNA variant in breast cancer
57. Tamoxifen activation of the estrogen receptor/AP-1 pathway: Potential origin for the cell-specific estrogen-like effects of antiestrogens
58. The estrogen receptor enhances AP-1 activity by two distinct mechanisms with different requirements for receptor transactivation functions
59. Comparative analyses of mechanistic differences among antiestrogens